Seminario web

The first Joint Clinical Assessment is here: What market access teams should learn now

The first Joint Clinical Assessment (JCA) offers one of the earliest practical views into how the European Health Technology Assessment Regulation (HTAR) may work in practice — and what that could mean for evidence planning, market access strategy, and launch readiness across Europe.

Key highlights

In this webinar, "Understanding the first JCAs: Practical takeaways for key stakeholders," Cencora and ISPOR, The Professional Society for Health Economics and Outcomes Research explore early lessons from the first JCA assessment and what they may signal for pharmaceutical companies preparing future submissions. The discussion looks beyond process readiness to a more pressing question: whether evidence packages are robust enough to withstand both European Union-level and national-level scrutiny.

Topics include the growing importance of comparative evidence, the risks associated with evidence gaps across multiple PICOs, and the commercial implications of public assessment outcomes that may influence downstream national decisions. Speakers also examine how cross-functional teams may need to adapt their operating models to support earlier evidence planning, stronger indirect comparison strategies, and more proactive management of uncertainty.

Watch the on-demand recording to hear practical takeaways for market access and health economics and outcomes research teams navigating the evolving EU HTA landscape.

Access the webinar recording to learn more

Pardot Form

Estamos aquí para ayudar

Póngase en contacto con nuestro equipo hoy mismo para obtener más información sobre cómo Cencora está ayudando a dar forma al futuro de la atención sanitaria.

Recursos relacionados

Guía

La guía esencial para la comercialización de fármacos

Seminario web

El potencial transformador de la IA en el HEOR y el acceso a los mercados

Artículo

Proyecciones peligrosas: Cómo las malas elecciones de modelos de supervivencia con datos inmaduros pueden desorientar las decisiones de HTA y afectar a los pacientes